NeuroFrontiers podcast

Can We Delay Alzheimer's Symptoms Before They Begin? Inside the PrevenTRON Trial

0:00
8:31
Rewind 15 seconds
Fast Forward 15 seconds
Episode description: Dr. Geoff Kerchner, Vice President and Global Head of Neurodegeneration at Roche, Basel, Switzerland, discusses the science behind PrevenTRON, a prevention study evaluating trontinemab in individuals with preclinical Alzheimer disease. Keywords: trontinemab, Alzheimer's, Alzheimer disease, dementia, mild cognitive impairment, MCI, amyloid-targeting therapies, Roche, PrevenTRON, TRONTIER, brain health, cognitive health

More episodes from "NeuroFrontiers"